An Updated Comparison of Drug Dosing Methods

SummaryThe resurgence of the use of and interest in vancomycin, in conjunction with the high degree of interpatient variability in its pharmacokinetic profile, has prompted the development of many and varied dosing methods. Several dosing nomograms have been proposed and evaluated, methods which are useful for initial dosing but do not allow for individualisation of dosage. Given these constraints, several investigators have attempted to apply conventional least-squares regression techniques and, more recently, Bayesian methodologies using either 1- or 2-compartment pharmacokinetic models.Comparative information evaluating algorithmic methods demonstrates that those of Moellering and Lake offer the least biased and most precise predictions of vancomycin dosage. Patient individualisation using conventional least-squares methodology offers some improvement over nomogram-based methods, both in predictive performance and in dosage adjustment once serum concentration data are available. Overall, the latest data indicate that regimens which incorporate Bayesian principles tend to give better results than nomogram-based or conventional least-squares dosing methods for this drug.Despite the advances in methods for dosing vancomycin, several questions remain to be answered. A lack of convincing evidence of a correlation between serum concentrations and therapeutic outcome has prompted debate over the need for serum concentration monitoring and, if it is needed, over which patient population would most benefit. Secondly, little comparative information is currently available as to the dosing of vancomycin in paediatric and neonatal patient populations. Several nomograms for initial dosing have been proposed, but only 2 have been subject to subsequent testing. Finally, information regarding cost-effectiveness and the quality of patient outcome is lacking from the current literature.

[1]  J. Rotschafer,et al.  Evaluation of a Two‐Compartment Bayesian Forecasting Program for Predicting Vancomycin Concentrations , 1989, Therapeutic drug monitoring.

[2]  G. Mccracken,et al.  Clinical pharmacology and efficacy of vancomycin in pediatric patients. , 1980, The Journal of pediatrics.

[3]  W. Keane,et al.  Pharmacokinetics of vancomycin in patients with various degrees of renal function , 1984, Antimicrobial Agents and Chemotherapy.

[4]  R. Slaughter,et al.  Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. , 1987, The American journal of medicine.

[5]  D. T. Rock,et al.  Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers , 1987, Antimicrobial Agents and Chemotherapy.

[6]  J. Sheagren Staphylococcus aureus: The Persistent Pathogen , 1984 .

[7]  T. Sorrell,et al.  A prospective study of adverse reactions associated with vancomycin therapy. , 1985, The Journal of antimicrobial chemotherapy.

[8]  D. T. Rock,et al.  Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. , 1988, The Journal of infectious diseases.

[9]  P. Elmes,et al.  Vancomycin: Report on Treatment of Patients with Severe Staphylococcal Infections , 1959, British medical journal.

[10]  G. Koren,et al.  Vancomycin pharmacokinetics and dose recommendations for preterm infants , 1987, Antimicrobial Agents and Chemotherapy.

[11]  J. Rotschafer,et al.  Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations , 1982, Antimicrobial Agents and Chemotherapy.

[12]  M. Rybak,et al.  Vancomycin pharmacokinetics in burn patients and intravenous drug abusers , 1990, Antimicrobial Agents and Chemotherapy.

[13]  R. Brummett,et al.  Vancomycin- and erythromycin-induced hearing loss in humans , 1989, Antimicrobial Agents and Chemotherapy.

[14]  M. Chandler,et al.  Short Communication; Using Clinical Data to Determine Vancomycin Dosing Parameters , 1990, Therapeutic drug monitoring.

[15]  D. Brater,et al.  Bayesian and Least‐Squares Methods for Vancomycin Dosing , 1987, The American journal of the medical sciences.

[16]  R. Kliegman,et al.  The Clinical Pharmacology of Vancomycin in Seriously Ill Preterm Infants , 1987, Pediatric Research.

[17]  R. Polin,et al.  Vancomycin pharmacokinetics in infants: relationships to indices of maturation. , 1986, Pediatric infectious disease.

[18]  R W Jelliffe,et al.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens , 1990, Antimicrobial Agents and Chemotherapy.

[19]  J. Rotschafer,et al.  Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.

[20]  M. Rybak,et al.  Nephrotoxicity of vancomycin, alone and with an aminoglycoside. , 1990, The Journal of antimicrobial chemotherapy.

[21]  M. Vasko,et al.  Comparison of Drug Dosing Methods , 1985, Clinical pharmacokinetics.

[22]  B. Farber,et al.  Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 , 1983, Antimicrobial Agents and Chemotherapy.

[23]  R. Blouin,et al.  Vancomycin pharmacokinetics in normal and morbidly obese subjects , 1982, Antimicrobial Agents and Chemotherapy.

[24]  G. Matzke,et al.  Clinical Pharmacokinetics of Vancomycin , 1986, Clinical pharmacokinetics.

[25]  D. Louria,et al.  Vancomycin in severe staphylococcal infections. , 1961, Archives of internal medicine.

[26]  R. Polk,et al.  Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions , 1990, Antimicrobial Agents and Chemotherapy.